Published on 18/11/2025
Making Confident Claims: Error Control and Subgroup Evaluation That Stand Up to Review
Why Multiplicity Matters and How Subgroup Questions Fit the Big Picture
Multiplicity arises whenever a trial makes more than one statistical claim—multiple endpoints (primary and key secondary), multiple time points, multiple doses, interim looks, populations (overall and biomarker-positive), or even many subgroup comparisons. Each comparison increases the chance of at least one false positive unless the design controls the experiment-wise risk. Global regulators—the U.S. FDA, the EMA, Japan’s Estimands first. Multiplicity plans must align with the estimands: which effects (treatment, population, endpoint definition, intercurrent event handling, summary) are being claimed? If co-primary endpoints define success only when all are positive, the error is inherently conservative; if success is declared when any of several endpoints succeed, formal multiplicity control is essential. For subgroup questions, the estimand might be the effect in a biomarker-positive stratum; in that case, the analysis hierarchy must show how alpha is allocated between overall and subgroup populations. Families, not fragments. Define the families of hypotheses that require protection. Typical families include: (1) the primary endpoint(s) in the overall intent-to-treat population; (2) key secondary endpoints intended for labeling claims; (3) population-specific claims (e.g., biomarker-positive); and, less often, (4) dose-response or regimen comparisons. Within each family, specify the gatekeeping logic and any recycling to other families to preserve the overall alpha budget. Subgroups and the lure of over-interpretation. Forest plots with dozens of subgroups are visually compelling, but the chance of spurious high/low effects is substantial. The confirmatory posture requires pre-specification of a small number of clinically motivated subgroup hypotheses and a valid test (often an interaction) within the multiplicity framework. All other subgroup displays should be clearly labeled as exploratory, with conservative interpretation. Operational reality. Multiplicity is not only mathematics. It affects sample size (alpha sharing reduces per-hypothesis power), the order in which endpoints are tested (and therefore which analyses are programmed first), and DMC/DSMB governance for interim looks. A design that ignores these linkages often leads to last-minute SAP amendments or ambiguous labeling negotiations—risks that can be avoided by anchoring multiplicity in the protocol and SAP from the outset. Control targets and philosophies. Most confirmatory programs control the family-wise error rate (FWER). In high-dimensional discovery settings (genomics), false discovery rate (FDR) control may be appropriate, but FDR is generally not accepted for pivotal endpoint claims. Choose the control target that matches the nature of the claims and justify it in the SAP. Single-family procedures. Hierarchies and gatekeeping. When families of endpoints are prioritized, gatekeeping preserves alpha by requiring success in an upstream family before testing the next. Options include: Graphical alpha-recycling frameworks. Graphical approaches represent endpoints as nodes, with alpha weights on edges that redistribute α when a node is rejected. They are highly flexible for complex programs (co-primaries, multiple doses, population claims, interims). The key to inspection-readiness is pre-specifying the graph, initial weights, and transfer rules in the SAP, and archiving simulations that show operating characteristics under realistic correlations among endpoints. Interim looks meet multiplicity. Group-sequential or alpha-spending designs consume α over time. When both interims and multiple endpoints exist, the alpha budget must be shared across time and families. Options include: (a) apply spending functions separately within each family using a graphical overlay; (b) create a master spending function for the family as a whole, then redistribute remaining α at each look. Whatever the approach, describe it unambiguously and verify through simulation that the overall FWER is preserved. One-sided versus two-sided claims. Clarify sidedness up front. Many agencies prefer two-sided 5% for pivotal efficacy even when a one-sided clinical claim is relevant. Mixed sidedness across endpoints complicates control and should be avoided unless there is a compelling scientific reason and clear justification. Precision and confidence intervals. Multiplicity control focuses on hypothesis testing, but decisions often rely on confidence intervals and effect sizes. Consider simultaneous CIs (e.g., Bonferroni-adjusted) for families of endpoints used in claims or labeling tables to maintain coherent inference. From curiosity to claim. Subgroup analyses seek to understand heterogeneity of treatment effect across baseline factors (age, sex, region), disease characteristics (severity, prior lines), or biomarkers. Most subgroup displays are descriptive and exploratory. A rare few are confirmatory claims (e.g., biomarker-defined population). Your SAP must identify which are which, and only the confirmatory ones receive alpha protection within the multiplicity plan. Pre-specify, then test interactions. The statistically coherent way to assess subgroup differences is through an interaction test in a single model (e.g., treatment × subgroup factor in ANCOVA or Cox). Testing within each subgroup without an interaction test can mislead. For ordered subgroups (e.g., severity quartiles), consider trend interactions. Define the exact coding (categorical vs continuous with splines) before lock. How many subgroups? Limit confirmatory subgroup hypotheses to a small, clinically motivated set. A long list dilutes power and invites false positives even with control methods. For broad descriptive exploration, produce forest plots with CIs and interaction p-values but avoid over-interpretation of single outliers—especially when sample sizes are small. Small-n subgroups and unstable estimates. In sparse subgroups, frequentist point estimates can be extreme. Shrinkage methods (e.g., Bayesian hierarchical models, empirical Bayes) borrow strength across subgroups to stabilize estimates while allowing differences. When used, describe the prior structure and show operating characteristics (bias/variance trade-off) in simulations. Such models are generally supportive unless prospectively declared for confirmatory claims. Multiplicity across subgroups. If multiple subgroup claims are sought (e.g., both biomarker-positive and -negative), allocate alpha across those hypotheses using gatekeeping or a graphical framework, and test interactions accordingly. Where only the biomarker-positive group is confirmatory, make the negative group supportive and interpret cautiously. Model selection and overfitting. Data-driven subgroup discovery (recursive partitioning, machine learning) is exploratory and must be labeled as such. If such methods feed future confirmatory trials, codify the algorithm and thresholds, then pre-specify them prospectively. Mixing discovery and confirmation in one study invites bias and regulatory challenge. Presentation that informs, not misleads. Good forest plots display effect estimates with CIs, number analyzed per subgroup, interaction p-values, and a vertical line at the overall effect. Use consistent scales (risk difference, log-HR). Avoid dichotomizing “significant vs not” per subgroup; emphasize patterns, uncertainty, and clinical relevance. Special contexts. Estimand alignment for subgroups. Ensure that the subgroup definition exists at randomization (baseline) and is measured consistently. For time-varying characteristics, define whether the subgroup is based on baseline value or a fixed prespecified post-baseline assessment and how intercurrent events affect subgroup membership under the estimand framework. What reviewers will ask for quickly. Keep a rapid-pull index that surfaces: (1) Protocol and SAP sections describing families of hypotheses, alpha budgets, and testing order; (2) any graphical alpha-recycling diagrams with initial weights and transfer rules; (3) simulations demonstrating family-wise error control and power across plausible correlations and effect patterns; (4) programming specifications linking each hypothesis to a TFL shell; (5) forest plot specifications (which subgroups, model forms, interaction terms); and (6) change-control records for any multiplicity or subgroup plan amendments. These artifacts align with expectations across the FDA, EMA, PMDA, TGA, the ICH community, and the WHO public-health lens. Simulation evidence is your safety net. Analytic guarantees exist for simple procedures, but complex alpha flows (multiple endpoints, interims, populations) require simulation to quantify operating characteristics. Simulate: (a) global null; (b) only primary true; (c) varying correlation between endpoints; (d) heterogeneous subgroup effects; (e) deviations from proportional hazards where relevant. Archive code, package versions, and random seeds; report power curves and realized FWER across scenarios. KPIs that show control. Common failure modes—and durable fixes. One-page checklist (study-ready multiplicity & subgroup plan). Bottom line. Multiplicity and subgroup analyses are not afterthoughts—they are core design features that shape what you can claim and how credible it will be. When you define hypothesis families, allocate and recycle alpha transparently, test heterogeneity with interaction models, and support complex designs with simulations and airtight documentation, your conclusions will resonate with assessors at the FDA, EMA, PMDA, TGA, the ICH community, and within the public-health mission of the WHO.The Multiplicity Toolbox: From Simple Adjustments to Graphical Alpha Flow
Subgroup Analyses Done Right: Planning, Testing, and Shrinkage for Credible Heterogeneity
Inspection-Ready Execution: Evidence, Simulations, Pitfalls, and a Practical Checklist